Consensus Molecular Subtypes (CMS) Classification: a progress towards Subtype-Driven treatments in colorectal cancer

CMS classification enhances CRC prognosis and treatment personalization but faces challenges due to ITH and technical limitations. Advances in IHC, imCMS, and targeted gene panels may facilitate broader clinical adoption, improving patient outcomes through tailored therapies.